Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Alexander J. Blood, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Om P. Ganda, MD
The effect of icosapent ethyl on CV events in metabolic syndrome
Michael Miller, MD
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
Carolyn Lam, MD, PhD
Maria Luiza Caramori, MD, PhD
Ana Maria Cebrián-Cuenca, MD, PhD
Pam R. Taub, MD, FACC, FASPC
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.